Evaluation of The Efficacy of Triazavirin Versus Oseltamivir in Egyptian Patients Infected With COVID-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-08-01

Study Completion Date

2021-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to evaluate the efficacy and safety (side effects and / or adverse effects) of Triazavirin and Oseltamivir as treatment of Coronavirus Disease 2019 in Egyptian patients in military hospitals.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19

NCT04360122

Coronavirus Disease (COVID-19)

UNKNOWN PHASE3

Levamisole and Isoprinosine in the Treatment of COVID19: A Proposed Therapeutic Trial

NCT04383717

Respiratory Tract Infections

UNKNOWN PHASE3

Efficacy and Safety of Favipiravir in Management of COVID-19

NCT04349241

Coronavirus Disease (COVID-19)

COMPLETED PHASE3

Remdesivir Efficacy In Management Of COVID-19 Patients

NCT04853901

Covid19

COMPLETED PHASE3

Comparison of Remdesivir Versus Lopinavir/ Ritonavir and Remdesivir Combination in COVID-19 Patients

NCT04738045

Covid19

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In December 2019, a series of pneumonia cases of unknown cause emerged, followed by a rapidly spread due to strong human-to-human transmission in china. Based on the clinical presentation, the pneumonia was determined to be a viral infection; the virus was initially named the 2019 novel coronavirus (2019-nCoV) and then, formally, severe acute respiratory syndrome coronavirus2 (SARS-CoV-2). Most districts have reported zero increase of coronavirus disease 2019 (COVID-19) cases since March 2020. As of 11 March 2020, a total of 80 955 laboratory-confirmed cases had been documented in China.

The World Health Organization (WHO) declared COVID-19 to be a public health emergency of international concern on 30 January 2020. The mortality rate was found to be 3.9% according to the data at that time. Given the human-to-human transmission and high infectivity of the disease, COVID-19 has been rapidly spreading in Republic of Korea, Iran, Italy, the United States, and Europe. A number of studies and reports have identified a median incubation period of 4 d and have determined that the top four symptoms include fever, cough, shortness of breath, and chest tightness/pain.

The most unfortunate fact is that there have been no effective therapies for preventing and treating COVID-19 to date. Although Remdesivir and Hydroxychloroquine have been found to be effective in inhibiting SARS-CoV-2, the data obtained thus far are primarily from in vitro studies, but their effectiveness in vivo still questionable. Interferon, Lopinavir/ritonavir, Arbidol, Ribavirin, and the therapeutic application of plasma antibodies have also been recommended as alternatives for the treatment of patients with COVID-19; however, the efficacy and safety of these drugs remain to be verified in patients, and their applications are yet to be validated by scientifically sound randomized clinical trials (RCTs).

Triazavirin (TZV), a new antiviral drug, has been on the market in Russia since 2015. It is a synthetic compound analogue to the purine nucleoside bases. The principle mode of action of TZV is inhibiting the synthesis of viral RNA and preventing the replication of genomic fragments. Because of its multiple-target mechanism of action, TZV has a wide spectrum of antiviral activity against RNA-containing viruses, including influenza A virus (H5N1, etc.), influenza B virus, tick-borne encephalitis, and Forest-Spring encephalitis, both in vitro and in animal models in vivo.

Oseltamivir is a first-line antiviral drug, especially in primary hospitals of military medical hospitals. During the ongoing outbreak of coronavirus disease 2019 (COVID-19), most patients with COVID-19 who are symptomatic have used Oseltamivir. Considering its popular and important role as an antiviral drug, it is necessary to evaluate oseltamivir in the treatment of COVID-19 . Oseltamivir inhibits the neuraminidase enzyme, which is expressed on the viral surface. The enzyme promotes release of virus from infected cells and facilitates viral movement within the respiratory tract. In the presence of neuraminidase inhibitors, virions stay attached to the membrane of infected cells and are also entrapped in respiratory secretions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Simple Randomization Parallel Double Blinded.

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

To ensure blindness one placebo capsule will be added to group B.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Triazavirin group

Patients will take the standard treatment COVID-19 + Triazavirin 250mg three times daily for 7 days\]

Group Type ACTIVE_COMPARATOR

standard treatment COVID-19 + Triazavirin

Intervention Type DRUG

to evaluate the efficacy and safety (side effects and / or adverse effects) of Triazavirin and Oseltamivir as treatment of Coronavirus Disease 2019

Oseltamivir group

Patients will take the standard treatment COVID-19 + Oseltamivir 75 mg twice daily for 7 days\]

Group Type ACTIVE_COMPARATOR

standard treatment COVID-19 + Triazavirin

Intervention Type DRUG

to evaluate the efficacy and safety (side effects and / or adverse effects) of Triazavirin and Oseltamivir as treatment of Coronavirus Disease 2019

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

standard treatment COVID-19 + Triazavirin

to evaluate the efficacy and safety (side effects and / or adverse effects) of Triazavirin and Oseltamivir as treatment of Coronavirus Disease 2019

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

standard treatment COVID-19 + Oseltamivir

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adults from 18 to 60 years old who signed informed consent;
2. Laboratory confirmed SARS-CoV-2 infection by real-time RT-PCR.
3. Chest computed tomography (CT) imaging-confirmed lung damage, including multiple small plaques and stromal changes in the lungs, which are obvious in the outer lung, or multiple ground-glass shadows and infiltration shadows in both lungs, although these changes might not be present in mild patients.
4. Patients with history of fever (axillary temperature more than 37°С) or respiratory symptoms.

Exclusion Criteria

1. Patients who are unsuitable or who cannot participate safely in the study, as judged by the principal investigator (PI).
2. Patients with serious liver disease (increase of liver transaminases enzymes).
3. Patients with severe renal impairment (denoted by increase serum urea \& serum creatinine) or continuous renal replacement therapy, hemodialysis, or peritoneal dialysis.
4. Patients with severe anemia.
5. Women with a positive pregnancy test, ongoing pregnancy, or who are breastfeeding.
6. Patients with a history of allergy to medications or its metabolic components.
7. Patients who have not signed informed consent.
8. Patients participating in other clinical trials for COVID-19 within 30 days prior to screening.
9. Patients participating in other clinical research in the past three months.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No